Hunt Warns Pharmaceutical Companies No Quick Fix for Financial Problems

Welcome to Financial Times, and thank you for your interest in our trial offer! We are excited to offer you complete digital access to FT.com with both of our Standard Digital and Premium Digital packages.

Standard Digital will give you access to a wealth of global news, analysis, and expert opinion from some of the world’s top journalists. With our exceptional reporting, you’ll gain insight into virtually any market and industry across the globe. Our reporters and columnists cover a wide range of topics, helping you stay informed on what’s important in business.

For those seeking an even deeper dive into business, Premium Digital is the way to go. Premium digital includes access to our premier business column, Lex, as well as 15 curated newsletters covering key business themes. Each newsletter offers original, in-depth reporting from the FT’s team of trained professionals.

If you already know that Standard Digital is all the digital access you need, then you may opt to downgrade to our robust journalistic offering. Standard Digital still consists of a full library of global news, analysis, and insights, just without the added content found in our Premium package. To compare both packages in greater detail and determine which one is best for you, please see our website.

We hope you find Financial Times to be a great source of information and knowledge. Thank you for joining us for this trial period and we look forward to having you as a reader.